Evolve Pharmacology hesi practice exam
questions with correct answers
A |client |who |has |been |taking |phenazopyridine |(Pyridium) |for |symptoms |of |urethritis |and |
cystitis |comes |to |the |clinic |because |her |urine |is |reddish-orange. |Which |question |should |the |
practical |nurse |ask |to |determine |if |the |medication |has |been |effective?
A) |How |much |water |have |you |been |drinking |each |day?
B) |Does |the |urine |color |stain |your |toilet |bowl |or |undergarments?
C) |Have |you |had |any |relief |from |urinary |pain, |burning, |or |urgency?
D) |Did |your |urine |appear |cloudy |or |have |a |foul |odor |on |voiding? |- |CORRECT |ANSWER✔✔-C) |
Have |you |had |any |relief |from |urinary |pain, |burning, |or |urgency?
Feedback:
Phenazopyridine, |an |over-the-counter |urinary |analgesic, |acts |on |the |mucosa |of |the |urinary |
tract |to |relieve |urinary |pain, |burning, |itching, |or |urgency |(C) |associated |with |urethritis |and |
cystitis. |Although |determining |if |the |client |is |forcing |fluids |(A), |experiencing |staining |from |
Pyridium's |side |effect |(B), |or |having |signs |of |a |urinary |infection |(D) |are |worthwhile |
assessments, |the |therapeutic |response |of |Pyridium |is |related |to |urinary |discomforts |only.
A |male |client |who |has |been |receiving |an |antineoplastic |drug |has |developed |
thrombocytopenia. |What |instructions |should |the |practical |nurse |(PN) |reinforce?
A) |Use |suppository |form |of |drugs.
B) |Avoid |large |public |gatherings.
C) |Rise |slowly |when |standing |up.
D) |Shave |with |an |electric |razor. |- |CORRECT |ANSWER✔✔-D) |Shave |with |an |electric |razor.
Feedback:
Thrombocytopenia |is |a |common |side |effect |of |bone |marrow |depression |caused |by |several |
antineoplastic |agents. |The |client |is |experiencing |a |low |platelet |count |and |should |use |an |
,electric |razor |(D) |to |reduce |his |risk |of |bleeding. |(A, |B, |and |C) |are |not |indicated |for |a |client |who
|needs |to |implement |thrombocytopenia |precautions.
The |practical |nurse |(PN) |is |caring |for |a |client |who |has |been |taking |prednisone |(Deltasone) |
daily |for |a |year. |Which |adverse |effect |should |the |PN |document |in |the |client's |record?
A) |Photosensitvity.
B) |Weight |gain.
C) |Loss |of |hair.
D) |Pale |skin |color. |- |CORRECT |ANSWER✔✔-B) |Weight |gain.
Feedback: |
Long |term |use |of |prednisone |causes |fluid |retention |and |redistribution |of |fat |deposition. |
Weight |gain |(B) |and |moon |face |reflect |adverse |effects |of |long-term |prednisone |use |and |should
|be |documented. |(A, |C, |and |D) |do |not |occur |with |treatment |using |prednisone.
A |female |client |with |recurring |headaches |tells |the |practical |nurse |(PN) |that |she |has |been |
taking |at |least |4 |grams |of |acetaminophen |a |day. |Which |laboratory |studies |should |the |PN |
review |for |this |client?
A) |Creatinine |clearance.
B) |Hepatic |enzymes.
C) |Coagulation |values.
D) |Arterial |blood |gases. |- |CORRECT |ANSWER✔✔-B) |Hepatic |enzymes.
Feedback: |
Liver |toxicity |can |occur |when |doses |of |acetaminophen |exceed |4 |grams |a |day, |resulting |in |an |
elevation |in |hepatic |enzyme |values |(B). |(A, |C, |and |D) |do |not |reveal |findings |related |to |
acetaminophen |toxicity.
A |client |receives |a |prescription |for |an |oral |opioid |analgesic |for |post-operative |pain. |Which |
adverse |effect |should |the |practical |nurse |(PN) |monitor |for |with |the |client?
A) |Constipation.
, B) |Photosensitivity.
C) |Decreased |heart |rate.
D) |Frequent |urination. |- |CORRECT |ANSWER✔✔-A) |Constipation.
Feedback: |
Opioid |analgesics |slow |peristalsis, |which |leads |to |constipation |(A), |a |common |side |effect |of |
opiates. |(B, |C, |and |D) |are |not |associated |with |opioid |analgesics.
Which |action |should |the |practical |nurse |implement |when |administering |a |buccal |medication?
A) |Encourage |the |client |to |swallow.
B) |Administer |water |with |medication.
C) |Ensure |the |medication |is |positioned |under |the |tongue.
D) |Place |the |medication |between |the |upper |molar |teeth |and |cheek. |- |CORRECT |ANSWER✔✔-
D) |Place |the |medication |between |the |upper |molar |teeth |and |cheek.
Feedback: |
Buccal |medications |are |placed |between |the |upper |molar |teeth |and |the |cheek |(D) |for |
absorption |by |the |capillaries |of |the |oral |mucosa. |The |client |should |be |cautioned |against |
swallowing, |not |(A). |Buccal |medications |are |not |administered |with |water |(B). |(C) |describes |
sublingual |administration.
What |assessment |is |most |important |for |the |practical |nurse |(PN) |to |obtain |prior |to |initiating |
medication |therapy |with |phenelzine |(Nardil) |for |a |client |with |depression?
A) |Activity |level.
B) |Mood |and |affect.
C) |Understanding |of |diet |modification.
D) |The |client's |support |system. |- |CORRECT |ANSWER✔✔-C) |Understanding |of |diet |modification.
Feedback: |
To |prevent |a |potentially |lethal |hypertensive |crisis, |a |tyramine-free |diet |should |be |maintained |
during |antidepressant |therapy |with |Nardil, |a |monoamine |oxidase |inhibitor |(MAOI). |It |is |most |
important |to |determine |if |the |client |understands |diet |modification |(C) |before |Nardil |is |initiated
questions with correct answers
A |client |who |has |been |taking |phenazopyridine |(Pyridium) |for |symptoms |of |urethritis |and |
cystitis |comes |to |the |clinic |because |her |urine |is |reddish-orange. |Which |question |should |the |
practical |nurse |ask |to |determine |if |the |medication |has |been |effective?
A) |How |much |water |have |you |been |drinking |each |day?
B) |Does |the |urine |color |stain |your |toilet |bowl |or |undergarments?
C) |Have |you |had |any |relief |from |urinary |pain, |burning, |or |urgency?
D) |Did |your |urine |appear |cloudy |or |have |a |foul |odor |on |voiding? |- |CORRECT |ANSWER✔✔-C) |
Have |you |had |any |relief |from |urinary |pain, |burning, |or |urgency?
Feedback:
Phenazopyridine, |an |over-the-counter |urinary |analgesic, |acts |on |the |mucosa |of |the |urinary |
tract |to |relieve |urinary |pain, |burning, |itching, |or |urgency |(C) |associated |with |urethritis |and |
cystitis. |Although |determining |if |the |client |is |forcing |fluids |(A), |experiencing |staining |from |
Pyridium's |side |effect |(B), |or |having |signs |of |a |urinary |infection |(D) |are |worthwhile |
assessments, |the |therapeutic |response |of |Pyridium |is |related |to |urinary |discomforts |only.
A |male |client |who |has |been |receiving |an |antineoplastic |drug |has |developed |
thrombocytopenia. |What |instructions |should |the |practical |nurse |(PN) |reinforce?
A) |Use |suppository |form |of |drugs.
B) |Avoid |large |public |gatherings.
C) |Rise |slowly |when |standing |up.
D) |Shave |with |an |electric |razor. |- |CORRECT |ANSWER✔✔-D) |Shave |with |an |electric |razor.
Feedback:
Thrombocytopenia |is |a |common |side |effect |of |bone |marrow |depression |caused |by |several |
antineoplastic |agents. |The |client |is |experiencing |a |low |platelet |count |and |should |use |an |
,electric |razor |(D) |to |reduce |his |risk |of |bleeding. |(A, |B, |and |C) |are |not |indicated |for |a |client |who
|needs |to |implement |thrombocytopenia |precautions.
The |practical |nurse |(PN) |is |caring |for |a |client |who |has |been |taking |prednisone |(Deltasone) |
daily |for |a |year. |Which |adverse |effect |should |the |PN |document |in |the |client's |record?
A) |Photosensitvity.
B) |Weight |gain.
C) |Loss |of |hair.
D) |Pale |skin |color. |- |CORRECT |ANSWER✔✔-B) |Weight |gain.
Feedback: |
Long |term |use |of |prednisone |causes |fluid |retention |and |redistribution |of |fat |deposition. |
Weight |gain |(B) |and |moon |face |reflect |adverse |effects |of |long-term |prednisone |use |and |should
|be |documented. |(A, |C, |and |D) |do |not |occur |with |treatment |using |prednisone.
A |female |client |with |recurring |headaches |tells |the |practical |nurse |(PN) |that |she |has |been |
taking |at |least |4 |grams |of |acetaminophen |a |day. |Which |laboratory |studies |should |the |PN |
review |for |this |client?
A) |Creatinine |clearance.
B) |Hepatic |enzymes.
C) |Coagulation |values.
D) |Arterial |blood |gases. |- |CORRECT |ANSWER✔✔-B) |Hepatic |enzymes.
Feedback: |
Liver |toxicity |can |occur |when |doses |of |acetaminophen |exceed |4 |grams |a |day, |resulting |in |an |
elevation |in |hepatic |enzyme |values |(B). |(A, |C, |and |D) |do |not |reveal |findings |related |to |
acetaminophen |toxicity.
A |client |receives |a |prescription |for |an |oral |opioid |analgesic |for |post-operative |pain. |Which |
adverse |effect |should |the |practical |nurse |(PN) |monitor |for |with |the |client?
A) |Constipation.
, B) |Photosensitivity.
C) |Decreased |heart |rate.
D) |Frequent |urination. |- |CORRECT |ANSWER✔✔-A) |Constipation.
Feedback: |
Opioid |analgesics |slow |peristalsis, |which |leads |to |constipation |(A), |a |common |side |effect |of |
opiates. |(B, |C, |and |D) |are |not |associated |with |opioid |analgesics.
Which |action |should |the |practical |nurse |implement |when |administering |a |buccal |medication?
A) |Encourage |the |client |to |swallow.
B) |Administer |water |with |medication.
C) |Ensure |the |medication |is |positioned |under |the |tongue.
D) |Place |the |medication |between |the |upper |molar |teeth |and |cheek. |- |CORRECT |ANSWER✔✔-
D) |Place |the |medication |between |the |upper |molar |teeth |and |cheek.
Feedback: |
Buccal |medications |are |placed |between |the |upper |molar |teeth |and |the |cheek |(D) |for |
absorption |by |the |capillaries |of |the |oral |mucosa. |The |client |should |be |cautioned |against |
swallowing, |not |(A). |Buccal |medications |are |not |administered |with |water |(B). |(C) |describes |
sublingual |administration.
What |assessment |is |most |important |for |the |practical |nurse |(PN) |to |obtain |prior |to |initiating |
medication |therapy |with |phenelzine |(Nardil) |for |a |client |with |depression?
A) |Activity |level.
B) |Mood |and |affect.
C) |Understanding |of |diet |modification.
D) |The |client's |support |system. |- |CORRECT |ANSWER✔✔-C) |Understanding |of |diet |modification.
Feedback: |
To |prevent |a |potentially |lethal |hypertensive |crisis, |a |tyramine-free |diet |should |be |maintained |
during |antidepressant |therapy |with |Nardil, |a |monoamine |oxidase |inhibitor |(MAOI). |It |is |most |
important |to |determine |if |the |client |understands |diet |modification |(C) |before |Nardil |is |initiated
